Activity of Fosfomycin and Amikacin against Fosfomycin-Heteroresistant Escherichia coli Strains in a Hollow-Fiber Infection Model
- 19 April 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (5)
Abstract
Objectives: To evaluate human-like intravenous doses of fosfomycin (8g/Q8h) and amikacin (15mg/kg/Q24h) efficacy in monotherapy and in combination against six fosfomycin-heteroresistant Escherichia coli isolates using a hollow-fiber infection model (HFIM). Materials and methods: Six fosfomycin-heteroresistant E. coli isolates (4 with strong mutator phenotype) and the control strain E. coli ATCC 25922 were used. Mutant frequencies for rifampin (100mg/L), fosfomycin (50 and 200mg/L) and amikacin (32mg/L) were determined. Fosfomycin and amikacin MICs were assessed by agar dilution (AD), gradient strip (GSA) and broth microdilution (BMD) assays. Fosfomycin and amikacin synergies were studied by checkerboard and time-kill assays at different concentrations. Fosfomycin (8g/Q8h) and amikacin (15mg/kg/Q24h) efficacy alone and in combination were assessed using a HFIM. Results: Five isolates were resistant to fosfomycin by AD and BMD, but all susceptible by GSA. All isolates were considered susceptible to amikacin. Antibiotic combinations were synergistic in two isolates and no antagonism was detected. In time-kill assays, all isolates survived under fosfomycin at 64mg/L, although, at 307mg/L, only the normomutators and two hypermutators survived. Four isolates survived under 16mg/L amikacin and none at 45mg/L. No growth was detected under combination conditions. In HFIM, fosfomycin and amikacin monotherapies failed to sterilise bacterial cultures, however, fosfomycin and amikacin combination showed a rapid eradication. Conclusions. There may be a risk of treatment failure of fosfomycin-heteroresistant E. coli isolates using either amikacin or fosfomycin in monotherapy. These results support that the combination amikacin-fosfomycin can rapidly decrease bacterial burden and prevent the emergence of resistant subpopulations against fosfomycin-heteroresistant strains.Keywords
Funding Information
- MEC | Instituto de Salud Carlos III (PI16/01824, REIPI RD12/0015/0010, REIPI RD16/0016/0001)
This publication has 37 references indexed in Scilit:
- Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin ResistanceAntibiotics, 2013
- Prevalence of acquired fosfomycin resistance among extended-spectrum -lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3Journal of Antimicrobial Chemotherapy, 2012
- Structural Basis of Substrate Selectivity in the Glycerol-3-Phosphate: Phosphate Antiporter GlpTBiophysical Journal, 2009
- Rapid and selective liquid chromatographic/tandem mass spectrometric method for the determination of fosfomycin in human plasmaJournal of Chromatography B, 2007
- Polymorphic Mutation Frequencies in Escherichia coli : Emergence of Weak Mutators in Clinical IsolatesJournal of Bacteriology, 2004
- Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitisJournal of Antimicrobial Chemotherapy, 2004
- Synergy, antagonism, and what the chequerboard puts between themJournal of Antimicrobial Chemotherapy, 2003
- A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided dosesJournal of Antimicrobial Chemotherapy, 1996
- Parenteral Aminoglycoside TherapyDrugs, 1994
- In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-livesJournal of Antimicrobial Chemotherapy, 1985